Αποτελέσματα Αναζήτησης
The TOUCH Prescribing Program is designed to: Inform prescribers, infusion center healthcare providers, and patients about the risk of progressive multifocal leukoencephalopathy (PML) associated with TYSABRI including the increased risk of PML with treatment duration and prior immunosuppressant use.
- Touch On-Line
TOUCH On-Line is a web-based tool designed to assist TOUCH...
- How to Enroll
Evaluate patients 3 months after the first infusion, 6...
- Touch On-Line
TOUCH On-Line is a web-based tool designed to: Provide real-time access to data for patients taking TYSABRI. Maintain compliance with the TOUCH Prescribing Program. Reduce administrative burden/paperwork for prescribers and infusion sites. Streamline communication to/from prescribers and infusion sites.
Τι είναι το Tysabri και ποια είναι η χρήση του. 2. Τι πρέπει να γνωρίζετε πριν πάρετε το Tysabri . 3. Πώς χορηγείται το Tysabri. 4. Πιθανές ανεπιθύμητες ενέργειες. 5. Πώς να φυλάσσετε το Tysabri. 6.
• TOUCH On-Line is a web-based tool designed to: – Provide real-time access to TYSABRI patient data – Maintain compliance with the TOUCH Prescribing Program
Read about the TOUCH Prescribing Program & what to expect when meeting with a TOUCH-authorized doctor in your area. See full safety & Boxed Warning.
Helpful Information for the Evaluation of New Neurological Symptoms in Patients Receiving TYSABRI. Understanding PML for Gastroenterologists material is a resource for Gastroenterologists, Internists, or other non-Neurology specialists treating TYSABRI patients.
Evaluate patients 3 months after the first infusion, 6 months after the first infusion, every 6 months thereafter to determine whether patients should continue on treatment, and for at least 6 months after discontinuing TYSABRI.
